Fig. 6From: Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccineClinical outcomes. a Time to radiographic progression using staging obtained at month 3 as baseline for evaluation. b Overall survival. c Serum PSA values collected for each patient pre-treatment and up to one year. d Pre-treatment and post-treatment PSA doubling times. For each panel, blue lines indicate patients treated in Arm 1, red lines indicate patients treated in Arm 2Back to article page